National Cancer Institute, Research Contracts Branch, PSAS, 6120 Executive Blvd, EPS/Room 638, Bethesda, MD 20892-7227

A -- RESEARCH & DEVELOPMENT SOL RFQ-NCI-80215 DUE 092198 POC Cynthia Brown, Purchasing Agent, 301-402-4509, Todd Cole, Contrating Officer The Biostatistics Branch (BB), Division of Cancer Epidemiology and Genetics (DCEG), National Cancer Institute (NCI) plans to procure the services of the Division of Infectious Diseases, Vanderbilt Univeristy, A-3310 Medical Center North, 1161 Twenty-first Avenue South, Nashville, Tn. 37232-2605 for assaying samples of cagA+strain of Helicobacter pylori(h.pylori). Recently, a study was completed for any analysis on the evolution of precancerous gastric lesion in Linqu County, Shandong Province of China. The data showed that the odds ratios (ORs) of progression to dysplasia (DYS) or gastric cancer (GC) rose from 1.4 to 2.2 to 4.7 for those with baseline diagnoses of severe chronic atrophic gastritis (CAG), superficial intestinal metaplasia (IM), and deep IM, respectively, compared to the subjects with superficial gastritis (SG) or mild CAG. 34 incident cases of GC varied from 17 to 29 and 104 for those with superficial IM, deep IM or CAGI+II or mild DYS and moderate or severe DYS at baseline, respectively, as compared to subjects with CAG. Since our earlier study Linqu showed that H. pylori infection is a risk factor for CAG, IM and DYS, and it would be interesting to learn the relation of Helicobacter pylori as well as the cagA+strain to the progression of precancerous gastric lesions, including the developing GC. Based on the results from Linqu studies, NCI plans to procure the services of the Division of Infectious Diseases, Vanderbilt University to perform a study on cagA+ strain of H. pylori relative to the progression of precancerous gastric lesions in Linqu. NCI will provide serum H. pylori from 2,800 subject, the government will provide approximately 2.0 ml of serum from each subject at -80 degrees Centigrade. The 2,800 serum samples shall be received in late September 1998. The Contractor shall performm laboratory tests of cagA+ for H. pylori, along with a duplicate test, using no more than .5 ml of the available serum. Since Vanderbilt Univeristy and Dr. Martin Blaser are internationally recognizedfor H.pylori testing and developed the cagA+ test that will be used in the current study, Vanderbilt Univeristy is the only source known to NCI that can meet the requirements of this study. If any interested party believes it can perform the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform this requirement. Capability statements must be received in the contracting office by 3:00 p.m. EST, on September 21, 1998. If you have any questions, Pllease contact Cynthia Brown, Purchasing Agent on (301) 402-4509. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competive procurement.The Standard Industiral Code is 8734. Posted 09/01/98 (W-SN244475). (0244)

Loren Data Corp. http://www.ld.com (SYN# 0007 19980903\A-0007.SOL)